SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2016 / Cilt: 44 - Sayı: Suppl. 4

Soru 48– Statin kullanan hastada KCFT yükselmesini ne zaman önemseyelim? Normalin üst sınırını 3 katına kadar yükselmesini bekleyelim mi?

Soru 48- Statin kullanan hastada KCFT yükselmesini ne zaman önemseyelim? Normalin üst sınırını 3 katına kadar yükselmesini bekleyelim mi?

Merih BAYKAN
Pages
73–74
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Eur Heart J 2011;32:1769–818

📌 3 Key Takeaways

🎯
Objective & Hypothesis:lipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
📊
Key Findings & Data:lipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
💡
Conclusion & Impact:Eur Heart J 2011;32:1769–818
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

lipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–818

Özet

Karaciğer; NÜS: Normalin üst sınırı; YTD: Yaşam tarzı değişikliği; İB: İndirek bilirübin; DB: Direk bilirübin; TB: Total bilirübin; NAFLD: Nonalkolik yağlı karaciğer hastalığı

🔖

Cite This Article

BAYKAN, M. (2022). Soru 48– Statin kullanan hastada KCFT yükselmesini ne zaman önemseyelim? Normalin üst sınırını 3 katına kadar yükselmesini bekleyelim mi?. Türk Kardiyoloji Derneği Arşivi, Cilt: 44 - Sayı: Suppl. 4, 73–74. https://ajindex.com/articles/632661

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007;11:597–613
  2. Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004;67:2175–86
  3. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):1–45
  4. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dys- lipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–818
  5. Rabar S, Harker M, O’Flynn N, Wierzbicki AS; Guideline Development Group. Lipid modification and cardiovascular risk assess- ment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014;349:4356.